AVXL Anavex Life Sciences
- 11.180
- +2.550+29.55%
- 11.260
- +0.080+0.72%
Anavex Life Sciences News
Anavex Life Sciences Analyst Ratings
H.C. Wainwright Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $40
Anavex Life Sciences Is Maintained at Buy by D. Boral Capital
Anavex Life Sciences Price Target Maintained With a $46.00/Share by D. Boral Capital
H.C. Wainwright Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $40
Anavex Life Sciences Analyst Ratings
Anavex Life Sciences: Buy Rating Driven by Promising Blarcamesine Developments and Market Expansion
JonesTrading Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $15
Anavex Life Sciences Is Maintained at Buy by EF Hutton
Anavex Life Sciences Analyst Ratings
H.C. Wainwright Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $40
Buy Rating Affirmed for Anavex Life Sciences Amid Promising Clinical Developments and Market Prospects
Buy Rating on Anavex Life Sciences Amid Anticipated European Approval and Market Opportunity for Alzheimer's Drug Blarcamesine
JonesTrading Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $15
Buy Rating on Anavex Life Sciences: Upcoming Catalysts and Positive Trial Outcomes Fuel Optimism
Anavex Life Sciences Analyst Ratings
Buy Rating Affirmed for Anavex Life Sciences on Blarcamesine's Promising Alzheimer's Treatment Potential
H.C. Wainwright Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $40
JonesTrading Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $15
Buy Rating Affirmed: Anavex Life Sciences' Promising Alzheimer's Drug Shows Potential for Approval
No Data